<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114153</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000432949</org_study_id>
    <secondary_id>UVACC-HIC-10519</secondary_id>
    <secondary_id>UVACC-27402</secondary_id>
    <secondary_id>BMS-UVACC-HIC-10519</secondary_id>
    <nct_id>NCT00114153</nct_id>
  </id_info>
  <brief_title>Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer</brief_title>
  <official_title>Phase I Trial of Induction Paraplatin® and Xeloda® Followed by Concurrent Paraplatin and Xeloda With Intensity Modulated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and capecitabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving&#xD;
      chemotherapy together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when&#xD;
      given together with carboplatin followed by radiation therapy in treating patients with stage&#xD;
      III or stage IV head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of capecitabine when administered with&#xD;
           carboplatin as induction chemotherapy in patients with stage III-IVB squamous cell&#xD;
           carcinoma of the head and neck.&#xD;
&#xD;
        -  Determine the MTD of capecitabine when administered with concurrent carboplatin and&#xD;
           intensity-modulated radiotherapy in these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of capecitabine.&#xD;
&#xD;
        -  Induction chemotherapy: Patients receive carboplatin IV on days 1, 8, 15, 22, 29, and 36&#xD;
           and oral capecitabine twice daily on days 1-14 and 22-35.&#xD;
&#xD;
        -  Concurrent chemoradiotherapy: Beginning 2 weeks after completion of induction&#xD;
           chemotherapy, patients receive carboplatin and capecitabine as in induction&#xD;
           chemotherapy. Patients also undergo intensity-modulated radiotherapy (IMRT) once daily&#xD;
           on days 1-5, 8-12, 15-19, 22-26, and 29-33 and non-IMRT boost once daily on days 36-40&#xD;
           and 43-47.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Within 4-8 weeks after completion of concurrent chemoradiotherapy, patients who achieve a&#xD;
      clinical complete response or who are medically operable with resectable persistent or&#xD;
      recurrent disease undergo neck dissection (salvage surgery).&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of capecitabine (during both induction&#xD;
      chemotherapy and concurrent chemoradiotherapy) until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose preceding that which 2 of 3 or 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, after completion of induction chemotherapy, and then&#xD;
      at 1 week and 3, 6, and 12 months after completion of concurrent chemoradiotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed monthly for 3 months and then every&#xD;
      3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 6-48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck, including 1 of&#xD;
             the following types:&#xD;
&#xD;
               -  Oral cavity&#xD;
&#xD;
               -  Oropharynx&#xD;
&#xD;
               -  Hypopharynx&#xD;
&#xD;
          -  Clinical stage III-IVB (T2-T4, N0-N3, M0) disease&#xD;
&#xD;
          -  Measurable disease by physical exam, endoscopy, and/or CT scan or MRI&#xD;
&#xD;
               -  Residual measurable disease after fine needle aspiration, core needle biopsy, or&#xD;
                  incisional or excisional biopsy of the primary tumor&#xD;
&#xD;
          -  No evidence of distant metastases (M1)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  No uncontrolled coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST &lt; 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No other clinically significant cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 30 days&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Nutritional and general physical condition must be compatible with proposed study&#xD;
             treatment&#xD;
&#xD;
          -  Mentally reliable&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No history of hypersensitivity to fluorouracil, capecitabine, or carboplatin&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No major medical, psychiatric, or neurologic illness that would preclude study&#xD;
             participation or giving informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 5 years since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for head and neck tumor&#xD;
&#xD;
          -  No prior radiotherapy to the region of planned study radiotherapy fields&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
               -  No unhealed surgical wounds&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No concurrent warfarin, diphenylhydantoin, or fluconazole unless willing to undergo&#xD;
             careful monitoring and appropriate dose adjustments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Y. Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul W. Read, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center at UV Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Thomas CY, Read P, Petroni G, Reibel J, Levine PA. Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer. Anticancer Res. 2009 Jul;29(7):2869-73.</citation>
    <PMID>19596976</PMID>
  </results_reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <last_update_submitted>November 25, 2009</last_update_submitted>
  <last_update_submitted_qc>November 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

